CCS is actively monitoring and responding to the recommendations of the Public Health Agency of Canada regarding coronavirus disease (COVID-19).
Consolidation therapy for multiple myeloma
Consolidation therapy for multiple myeloma is given after a stem cell transplant. It’s a short course of chemotherapy that helps make the previous chemotherapy treatment and stem cell transplant work better. Consolidation therapy also helps to keep the multiple myeloma in remission for longer.
Consolidation therapy for people with multiple myeloma who have had a stem cell transplant is most often the VRD regimen. The VRD regimen uses bortezomib (Velcade), lenalidomide (Revlimid) and dexamethasone (Decadron, Dexasone).
Together we can reduce the burden of cancer
Last year, we only had the resources available to fund 40% of high-priority research projects. Imagine the impact we could have if we were able to fund 100%.